Spero Therapeutics, Inc.

Cambridge, MA

UEI
NX34PL7NZW24
CAGE
7SK81
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
675 Massachusetts Ave, Cambridge, MA 02139, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 -$537,178
FY2025 $6,360,502
FY2024 $15,763,277
FY2023 $4,987,205

Contract awards

Award Agency Obligated Awarded
To advance clinical and non-clinical development of an antibiotic candidate. 75N93021C00022 National Institute of Allergy and Infectious Diseases (NIH) $10,501,521
Deobligate and close out the contract 75A50118C00015 Office of the Assistant Secretary for Preparedness and Response $49,196,134
"development of a second generation polymyxin for therapy of MDR gram-negative infections" HHSN272201500014C National Institute of Allergy and Infectious Diseases (NIH) $5,923,719

Grant awards

Award Agency Obligated Awarded
Development of SPR206, a direct acting polymyxin antibiotic with reduced nephrotoxicity, to treat multidrug-resistant… W81XWH1910295 Defense Health Agency $5,882,265

Quick answers

Is Spero Therapeutics, Inc. registered in SAM.gov?

Yes. Spero Therapeutics, Inc.'s SAM.gov registration is active through July 2, 2027.

What is Spero Therapeutics, Inc.'s CAGE code?

Spero Therapeutics, Inc.'s CAGE code is 7SK81, and its Unique Entity ID (UEI) is NX34PL7NZW24.

How much has Spero Therapeutics, Inc. received in federal contracts?

Federal contracts obligated $6,360,502 to Spero Therapeutics, Inc. in fiscal year 2025 and $26,573,807 in fiscal years 2023 through 2027.

How does Spero Therapeutics, Inc. rank among federal contractors?

Spero Therapeutics, Inc. ranked #44 in PSC AN13 and #59 in NAICS 541714 in FY2025.

What is Spero Therapeutics, Inc.'s most recent federal award?

Spero Therapeutics, Inc.'s most recent federal contract award is To advance clinical and non-clinical development of an antibiotic candidate (75N93021C00022), from National Institute of Allergy and Infectious Diseases (NIH), on May 17, 2021.

On GovTribe

See Spero Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe